This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

23 Apr 2012

Lesinurad to Be Prescribed to 10Pc of US Gout Patients

A report by Decision Resources predicts that lesinurad will soon earn a five per cent patient share in the US chronic gout market.

A survey of US rheumatologists suggests that Ardea Biosciences' Lesinurad may be prescribed to around ten per cent of patients with chronic gout.


In light of Decision Resources' survey, the research and advisory firm to the pharmaceutical market predicts that the drug will earn a five per cent patient share in the chronic gout market by 2020.


The company alluded to the therapy's robust safety profile and efficacy in its report, entitled 'Chronic Gout: Lesinurad's Efficacy Advantages Make it the Strongest Contender in the Pipeline for Chronic Gout Therapies'.


Decision Resources also commented on the strong clinical profile of Savient's Krystexxa (pegloticase), which is designed to treat severe t

Related News